This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.

This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. The evaluations will include clinical assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from three locations. Data will be collected on the amount of P-SYN in cutaneous nerve fibers. The cohorts of interest are as follows:

1. 100 participants with Long COVID-19 defined by NIH PASC criteria
2. 100 participants with acute COVID-19 who tested positive for COVID-19 without persistent symptoms defined WHO criteria
3. 50 participants with postural orthostatic tachycardia syndrome (POTS)
4. 50 participants with diabetic neuropathy

There are no plans for additional visits at this time.

If interested to learn more about this study, please complete the form here for someone to contact you. "here" would take you to the said form.

Inclusion Criteria, just one of the following:

• Long COVID-19 defined by NIH PASC criteria OR
• Acute COVID-19 who tested positive for COVID-19 without persistent symptoms OR
• Postural orthostatic tachycardia syndrome (POTS) OR
• Diabetic neuropathy

Exclusion Criteria:

• Clinical evidence of severe peripheral vascular disease
• History of ulceration, poor wound healing or vascular claudication
• History of allergic reaction to local anesthesia (for biopsy collection)
• Use of oral anticoagulants (aspirin or Plavix alone is allowed)
• History of a bleeding disorder

Male and females ages 18-80 who have been diagnosed with one of the following:

1. Long COVID defined by NIH PASC criteria OR 2. Acute COVID who tested positive for COVID without persistent symptoms OR 3. Postural orthostatic tachycardia syndrome (POTS) OR 4. Diabetic neuropathy